Robert A. Lenz - Oct 9, 2024 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Head of R&D
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Robert A. Lenz
Stock symbol
NMRA
Transactions as of
Oct 9, 2024
Transactions value $
-$208,110
Form type
4
Date filed
10/11/2024, 04:10 PM
Previous filing
Sep 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NMRA Common Stock Sale -$83.5K -5.56K -1.69% $15.01 323K Oct 9, 2024 Direct F1, F2
transaction NMRA Common Stock Sale -$125K -8.26K -2.56% $15.09 315K Oct 10, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024.
F2 This transaction was executed in multiple trades in prices ranging from $15.00 to $15.065, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 This transaction was executed in multiple trades in prices ranging from $15.00 to 15.2435, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.